-
Mashup Score: 0
Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The Cancer News Daily - 1 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/fxtVS3uj8b Thanks to @CathyEngMD @CancerNetwrk @OncLive #esmo2022 #lcsm
-
-
Mashup Score: 2
Julien Maziéres, MD, PhD, explains the importance of defining a second-line standard of care in the EGFR-mutated non–small cell lung cancer population, highlights the long-term benefits seen with tepotinib plus osimertinib, and previews the next steps that should be taken toward more individualized patient care.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tepotinib plus osimertinib is a promising combination in patients with osimertinib-pretreated, EGFR-mutated, MET amplified non–small cell lung cancer. @JulienMazieres @myESMO #lcsm #ESMO2022 https://t.co/9qB70fm09t https://t.co/z5ivliFpDI
-
-
Mashup Score: 0
The FDA has granted a fast track designation to AL102 for the treatment of patients with progressing desmoid tumors.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Interim data from part A of the pivotal phase 2/3 RINGSIDE trial showed that AL102 elicited responses and tumor shrinkage in patients with desmoid tumors. @US_FDA @myESMO #ESMO2022 https://t.co/p4Jty2nGO9 https://t.co/XvgNT3YHii
-
-
Mashup Score: 1
Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival and overall survival vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer regardless of PD-L1 expression level.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from the KEYNOTE-407 trial showed that at a median follow-up of 56.9 months, the median OS was 17.2 months with pembrolizumab vs 11.6 months with placebo. @myESMO #lcsm #ESMO2022 https://t.co/O0A66Zbrlu https://t.co/WQwuAGdA8Q
-
-
Mashup Score: 2
TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors. @ben_schlechter @DanaFarber @myESMO #stcsm #ESMO2022 https://t.co/gdJknwVLcZ
-
-
Mashup Score: 0
The addition of AZD4635 to durvalumab or oleclumab did not elicit significant responses in heavily pretreated patients with metastatic castration-resistant prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a phase 2 trial of patients with mCRPC, only 1 objective response was achieved in a patient treated with AZD4635 plus durvalumab, and no responses were achieved in those who received AZD4635 and oleclumab. @columbiacancer @myESMO #pcsm #ESMO2022 https://t.co/05GdvkSmQd https://t.co/Wg8RWAN00O
-
-
Mashup Score: 0
Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@adasarimd, of @MDAndersonNews, discusses the results of the FRESCO-2 trial of fruquintinib in patients with refractory mCRC, the significance of the data, and the potential next steps for examining the agent in this disease. @myESMO #crcsm #ESMO2022 https://t.co/0vPij9mjMp
-
-
Mashup Score: 0
Julien Maziéres, MD, PhD, explains the importance of defining a second-line standard of care in the EGFR-mutated non–small cell lung cancer population, highlights the long-term benefits seen with tepotinib plus osimertinib, and previews the next steps that should be taken toward more individualized patient care.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@JulienMazieres explains the importance of defining a second-line SOC in EGFR-mutated NSCLC, long-term benefits seen w/ tepotinib & osimertinib, & the next steps that should be taken toward more individualized patient care. @myESMO #lcsm #ESMO2022 https://t.co/eynsNm4JU2
-
-
Mashup Score: 0
Sunvozertinib provided beneficial antitumor activity when used as a second- or later-line treatment in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with NSCLC treated with sunvozertinib in the WU-KONG6 trial achieved a confirmed objective response rate of 59.8%. @myESMO #lcsm #ESMO2022 https://t.co/GYbvVAdfVp https://t.co/fsbG2jWm6l
-
WATCH: Dr Domenica Lorusso, of @FondaPoliMi, reviews data updates from KEYNOTE-775 that were recently presented at #ESMO2022. @myESMO #oncology #MedTwitter https://t.co/vqbKsPK1J6 https://t.co/XzTnLEXGrv